Asian Study on Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation Observing Patient Outcomes and Treatment Responses

What this Trial Is About

Researchers are investigating the characteristics and clinical outcomes of advanced non-small cell lung cancer NSCLC patients in Asia who have a specific genetic change called EGFR exon 20 insertion mutation. This study aims to improve understanding of how different forms and locations of this mutation affect patient responses to new targeted therapies. It addresses a current gap in detailed knowledge about this condition in the Asian population. This is a multi-center observational study enrolling about 600 patients retrospectively from various countries across Asia, including Hong Kong, Korea, Singapore, Taiwan, and Thailand. Patients included have advanced NSCLC with confirmed EGFR exon 20 insertion mutations identified through approved local tests. The study does not involve experimental treatments but collects data on patients clinical management and outcomes. Participants medical records will be reviewed to gather information on survival, therapy durations, and disease progression over up to 10 years. The primary measures include overall survival, duration of therapy, and real-world progression-free survival. This long-term data collection will help researchers better understand the disease course and treatment effectiveness in this patient group.

A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC